In a sample set of 47 ovarian carcinomas and 21 normal tissue samples, CapG overexpression was determined in 38% of all tumor samples (18/47), which was concordant to previous results based on cancer profiling arrays [13]. This evidence concerns the gene CAPG and neoplasm.